focus -WSS

focus

author：explore 2025-10-04 04:00:41 - browse：1762

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Organ aging and disease risk measured by new blood test

hotspot

focus

WSS

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Medicare has a new plan to address drug shortages

ReNAgade cuts staff seven months after raising $300 million

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

With clinical trial data readouts, here's how to spot spin

FDA approves RSV monoclonal antibody for infants, toddlers

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

Alkermes shareholders re

Disappointing trial forces Pfizer to pivot on obesity medicine plans

After affirmative action ruling, medical educators look to 'holistic review'

Sanofi seeks simpler, safer CRISPR sickle cell cure

State Dept. review finds Biden bears some blame for Afghanistan failures

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

At least 13 dead in Texas as scorching temps continue

How dance can help nurses traumatized by Covid

Supreme Court strikes down use of affirmative action

Startup Neumora takes a novel depression drug to Phase 3

hotspot

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Group opposing PBM reform sets lobbying record

Will the market for weight loss drugs really reach $100 billion?

Flagship Pioneering launches a new biotech in two countries

Flagship Pioneering launches a new biotech in two countries

hotspot

focus

focus

leisure time